Shares of leading fertility benefits manager Progyny(NASDAQ: PGNY) were down 19% as of 4 p.m. ET on Wednesday, according to data provided by S&P Global Market Intelligence.
The upstart healthcare company reported its results for the third quarter yesterday, missing analysts' expectations on the top line, delivering only 2% growth during the third quarter. Making matters worse, Progyny didn't assuage the market's fears by guiding for Q4 sales growth of only 1.5% at the midpoint, prompting many Wall Street experts to lower their price targets on the stock.
Progyny's worrisome quarter
During the third quarter, Progyny grew its member count by a promising 19% to 6.4 million lives covered. However, due to sequentially lower utilization rates between Q2 and Q3 -- which CEO Peter Anevski says the company has never seen before -- the company's revenue growth was nowhere near expectations.
The loss of one of its largest customers (believed to be Amazon) also played a role in this sales miss, but management believes it only accounted for 1.4 percentage points' worth of the decline in growth. Since Progyny's revenue growth rates have slowed from triple digits as recently as 2020 to barely positive today, the market seems somewhat justified in sending the company's shares down 79% from their all-time highs.
Despite this slowdown, however, Progyny remains the leader in its fertility niche. With the Centers for Disease Control and Prevention (CDC) estimating that 1 in 5 couples struggle with infertility across the United States -- up from 1 in 8 in 2019 -- Progyny's offerings grow more necessary by the day.
Trading at 22 times this year's earnings and 9 times next year's, Progyny could be a steal for investors if it can continue growing its member count, return to average utilization rates, and maintain its status as the best-in-class provider.
Should you invest $1,000 in Progyny right now?
Before you buy stock in Progyny, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Progyny wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $908,737!*
Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. TheStock Advisorservice has more than quadrupled the return of S&P 500 since 2002*.
*Stock Advisor returns as of November 11, 2024
John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Josh Kohn-Lindquist has positions in Progyny. The Motley Fool has positions in and recommends Amazon and Progyny. The Motley Fool has a disclosure policy.
